Avenue Therapeutics Stock Buy Hold or Sell Recommendation
| ATXI Stock | USD 2.15 0.09 4.37% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Avenue Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Avenue Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Avenue Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide. In addition, we conduct extensive research on individual companies such as Avenue and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Avenue |
Execute Avenue Therapeutics Buy or Sell Advice
The Avenue recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Avenue Therapeutics. Macroaxis does not own or have any residual interests in Avenue Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Avenue Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Avenue Therapeutics Trading Alerts and Improvement Suggestions
| Avenue Therapeutics generated a negative expected return over the last 90 days | |
| Avenue Therapeutics has high historical volatility and very poor performance | |
| Avenue Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Avenue Therapeutics currently holds about 890 K in cash with (9.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Avenue Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Avenue Therapeutics director Jay Kranzler sells 136 in stock |
Avenue Therapeutics Returns Distribution Density
The distribution of Avenue Therapeutics' historical returns is an attempt to chart the uncertainty of Avenue Therapeutics' future price movements. The chart of the probability distribution of Avenue Therapeutics daily returns describes the distribution of returns around its average expected value. We use Avenue Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Avenue Therapeutics returns is essential to provide solid investment advice for Avenue Therapeutics.
| Mean Return | -0.15 | Value At Risk | -6.13 | Potential Upside | 6.81 | Standard Deviation | 4.35 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Avenue Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Avenue Stock Institutional Investors
| Shares | Armistice Capital, Llc | 2024-09-30 | 115 K | Sabby Management Llc | 2024-06-30 | 37.4 K | Moss Adams Wealth Advisors Llc | 2024-09-30 | 11 K | Tower Research Capital Llc | 2024-06-30 | 3.2 K | Ubs Group Ag | 2024-06-30 | 673 | Wells Fargo & Co | 2024-06-30 | 61.0 | Royal Bank Of Canada | 2024-06-30 | 8.0 | Emfo, Llc | 2024-06-30 | 8.0 | Bank Of America Corp | 2024-06-30 | 7.0 | Jpmorgan Chase & Co | 2024-06-30 | 1.0 |
Avenue Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Avenue Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Avenue Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Avenue stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | -0.09 | |
σ | Overall volatility | 4.26 | |
Ir | Information ratio | -0.07 |
Avenue Therapeutics Volatility Alert
Avenue Therapeutics exhibits very low volatility with skewness of 0.59 and kurtosis of 1.44. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Avenue Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Avenue Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Avenue Therapeutics Fundamentals Vs Peers
Comparing Avenue Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Avenue Therapeutics' direct or indirect competition across all of the common fundamentals between Avenue Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Avenue Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Avenue Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Avenue Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Avenue Therapeutics to competition |
| Fundamentals | Avenue Therapeutics | Peer Average |
| Return On Equity | -5.35 | -0.31 |
| Return On Asset | -2.01 | -0.14 |
| Current Valuation | 1.34 M | 16.62 B |
| Shares Outstanding | 1.91 M | 571.82 M |
| Shares Owned By Insiders | 9.85 % | 10.09 % |
| Shares Owned By Institutions | 10.33 % | 39.21 % |
| Number Of Shares Shorted | 44.05 K | 4.71 M |
| Price To Earning | (10.52) X | 28.72 X |
| Price To Book | 1.51 X | 9.51 X |
| EBITDA | 4.05 M | 3.9 B |
| Net Income | (10.38 M) | 570.98 M |
| Cash And Equivalents | 890 K | 2.7 B |
| Cash Per Share | 0.60 X | 5.01 X |
| Total Debt | 1.2 M | 5.32 B |
| Debt To Equity | 23.40 % | 48.70 % |
| Current Ratio | 2.47 X | 2.16 X |
| Book Value Per Share | 4.63 X | 1.93 K |
| Cash Flow From Operations | (9.45 M) | 971.22 M |
| Short Ratio | 0.73 X | 4.00 X |
| Earnings Per Share | 24.78 X | 3.12 X |
| Target Price | 8.0 | |
| Number Of Employees | 3 | 18.84 K |
| Beta | -0.18 | -0.15 |
| Market Capitalization | 3.94 M | 19.03 B |
| Total Asset | 1.85 M | 29.47 B |
| Retained Earnings | (90.93 M) | 9.33 B |
| Working Capital | 654 K | 1.48 B |
| Current Asset | 111.05 K | 9.34 B |
| Current Liabilities | 4.67 M | 7.9 B |
| Net Asset | 1.85 M |
Note: Acquisition by David Jin of 250000 shares of Avenue Therapeutics at 1.14 subject to Rule 16b-3 [view details]
Avenue Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Avenue . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Avenue Therapeutics Buy or Sell Advice
When is the right time to buy or sell Avenue Therapeutics? Buying financial instruments such as Avenue Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Avenue Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials ETFs Thematic Idea Now
Financials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Avenue Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.